Wednesday, April 01, 2020 8:41:28 AM
Icecure Medical Ltd ICUSF:Grey Market
IceCure Medical Continues Expansion in Asia; Receives Largest Purchase Order for ProSense(TM) Cryoablation System
PR Newswire
8:00 AM ET
IceCure Medical Ltd (TASE: ICCM), a developer and marketer of minimally invasive cryoablation therapies for women's health and Interventional oncology markets, announced today that it has received its largest purchase order (PO) for ProSense(TM) system from Bumrungrad International Hospital, a leading hospital based in Thailand. The order, which includes systems and probes is expected to be delivered and installed by the end of the second quarter. If travel restrictions continue due to the ongoing COVID-19 pandemic, the IceCure team has developed a strategy to deliver the system and provide remote support, installation and training to enable rapid access of its safe and effective, non-surgical cryoablation treatment to patients in Thailand.
"This is a significant achievement for IceCure and it demonstrates our continued efforts to expand our presence in key markets, such as Asia, where there is a great need for advanced solutions to treat cancer," commented Eyal Shamir, Chief Executive Officer. "During these unsettling times, global healthcare institutions are continuing to evaluate oncology solutions, and the benefits of our minimally invasive ProSense(TM) system eliminates the need to have the patient in an operating room (OR) environment. This is a critical and distinct advantage during normal times, but it is especially important now as the COVID-19 pandemic primarily targets those with underlying health conditions and weakened immune systems, such as those with cancer. Bumrungrad's decision, and that of others that currently evaluating ProSense(TM), highlights a patient-first approach and ensuring these patients are cared for in safer environments."
"IceCure's innovative minimally-invasive ProSense(TM) cryoablation system is consistent with our strategy to adopt cutting-edge, world-class technologies to advance patient care," said Jeremy Ford, Laboratory Research & Technology Director from Bumrungrad International Hospital. "By reducing operating room procedures, the ProSense(TM) system brings significant benefits in enabling a safe and effective alternative treatment for our oncology patients."
Bumrungrad International Hospital has been a global pioneer in providing world-class healthcare services and international patient support for nearly four decades. Located in the heart of Bangkok, Thailand, it is an internationally accredited, multi-speci alty hospital and one of the largest private hospitals in Southeast Asia, caring for over 1.1 million patients from more than 190 countries annually.
The Company is in discussion with Terumo, one of the world's leading medical device manufacturers, its exclusive distribution partner in Japan and Singapore, to also include Thailand and help accelerate the commercialization and utilization of ProSense(TM) cryoablation system throughout the country.
The Company's ProSense(TM) system is an effective liquid nitrogen (LN2) cryoablation solution, capable of destroying tumors safely, quickly and painlessly, without the need for surgery. Guided by CT or ultrasound, the probe is inserted into the tumor and liquid nitrogen generates sub-zero temperatures to turn the tumor into an ice ball. A freeze-thaw-freeze cycle destroys the targeted tissue immediately and leaves adjacent healthy tissue undamaged. The necrotic debris is eventually absorbed by the body.
About IceCure Medical
Founded in 2006, IceCure Medical (TASE: ICCM) is an Israeli medical device company that develops and markets an advanced liquid-nitrogen-based cryoablation therapy for women's health and the interventional oncology market, with the primary focus ar eas being breast, kidney and lung cancer. Its technology is a safe, effective, non-invasive alternative to surgical tumor removal that is easily performed in a short procedure. The system has US FDA 510k and CE Mark clearance and is sold worldwide. The company has a wholly-owned subsidiary in the United States, IceCure Medical Inc., with offices in New Jersey. To learn more, please visit: www.icecure-medical.com.
https://c212.net/c/img/favicon.png?sn=LN67318&sd=2020-04-01
View original content:http://www.prnewswire.com/news-releases/icecure-medical-continues-expansion-in-asia-receives-largest-purchase-or der-for-prosense-cryoablation-system-301033253.html
SOURCE IceCure Medical
https://rt.prnewswire.com/rt.gif?NewsItemId=LN67318&Transmission_Id=202004010800PR_NEWS_USPR_____LN67318&DateId=20200401
Business Wire is a registered trademark of Business Wire. GlobeNewswire is a registered trademark of The NASDAQ OMX Group, Inc. PR Newswire is a registered trademark of PR Newswire Association, Inc.
Please do not reply to this e-mail from Markit On Demand. Markit On Demand and TD Ameritrade are separate unaffiliated companies and are not responsible for each other's service. For questions regarding your brokerage account, please contact TD Ameritrade Client Services at 1-800-669-3900.
To stop receiving this alert from TD Ameritrade, please click here to update your subscription settings. You may also unsubscribe from all of your alerts using the link above. As always, you can manage all of your alert settings by logging into your TD Ameritrade account and navigating to Research & Ideas > Alerts.
Recent ICCM News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2024 12:40:03 PM
- Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally • PR Newswire (US) • 05/07/2024 12:30:00 PM
- IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer • PR Newswire (US) • 04/15/2024 12:35:00 PM
- IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance • PR Newswire (US) • 04/03/2024 12:30:00 PM
- U.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge Higher • IH Market News • 04/03/2024 11:11:59 AM
- IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes • PR Newswire (US) • 04/02/2024 12:30:00 PM
- IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 • PR Newswire (US) • 03/27/2024 12:30:00 PM
- IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy • PR Newswire (US) • 03/19/2024 12:30:00 PM
- IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes • PR Newswire (US) • 03/12/2024 12:30:00 PM
- IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference • PR Newswire (US) • 03/07/2024 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 01:35:29 PM
- IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 • PR Newswire (US) • 03/04/2024 01:30:00 PM
- Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop • PR Newswire (US) • 02/27/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 01:15:29 PM
- Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer • PR Newswire (US) • 02/26/2024 01:00:00 PM
- IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan • PR Newswire (US) • 02/15/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 01:15:02 PM
- U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer • PR Newswire (US) • 01/30/2024 01:00:00 PM
- IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class • PR Newswire (US) • 01/29/2024 01:00:00 PM
- IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation • PR Newswire (US) • 01/16/2024 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/12/2024 09:39:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/12/2024 09:18:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/12/2024 09:10:20 PM
- IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule • GlobeNewswire Inc. • 01/12/2024 09:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/10/2024 01:15:26 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM